Sclerostin epitopes

Details for Australian Patent Application No. 2012216589 (hide)

Owner UCB Pharma S.A. Amgen Inc.

Inventors Hoffmann, Kelly Sue; Henry, Alistair James; Winters, Aaron George; Winkler, David; Robinson, Martyn Kim; Lu, Hsieng Sen; Lawson, Alastair; Paszty, Christopher; Latham, John

Agent Davies Collison Cave

Pub. Number AU-A-2012216589

Parent 2006242476

Filing date 31 August 2012

Wipo publication date 20 September 2012

International Classifications

C07K 14/51 Peptides having more than 20 amino acids

A61K 38/10 Medicinal preparations containing peptides - Peptides having 12 to 20 amino acids

A61K 38/17 Medicinal preparations containing peptides - from animals

Event Publications

13 September 2012 Complete Application Filed

20 September 2012 Application Open to Public Inspection

  Published as AU-A-2012216589

20 September 2012 Corrigenda

  Complete Applications Filed - Name Index Under the name UCB Pharma S.A., Application No. 2012216589, under INID (54) correct the title to read Sclerostin epitopes

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012216590-Modified-release formulations of a bupropion salt

2012216588-Methods and apparatus for streamer positioning during marine seismic exploration